Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

DNA segments that can move from one part of the genome to another -- are key to bacterial evolution and the development of antibiotic resistance. Researchers have discovered a new mechanism these ...

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...

Screening for HIV, HBV, HCV, and Treponema pallidum was conducted using the Cobas e 601 system (Roche Diagnostics). A 100 μL volume of each donor’s plasma was utilized for viral RNA extraction with ...

Inverse probability treatment weighting balanced confounding factors. Complete virological response (CVR, HBV DNA < 20 IU/mL) and partial virological response (PVR, HBV DNA ≥ 20 IU/mL) were defined.

Worldwide, hepatitis B is thought to be the second deadliest infection; about 5% of the global population are infection and it can lead to liver cancer. | Microbiology ...

the Risca lab analyzed how HBV's DNA interacts with host histones to form chromatin structures. Their work confirmed that the mini-chromosome closely resembled how HBV's genome organizes in infected ...

The presence and the positioning of nucleosomes on DNA can be important in directing cellular mechanisms to transcribe some genes. We found that to be the case for the HBV gene encoding protein X — ...

Atomic force microscopy images show hepatitis B DNA in its natural state ... The Risca Lab studies the 3D architecture of the genome and how the packaging of DNA helps to control the transcription ...